Results 81 to 90 of about 205,631 (301)
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Radiation Oncology, 2018 Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells.
Zool Hilmi Awang +2 more
doaj +1 more source
Advanced Science, EarlyView.Dendritic cells (DC) vaccine is an important type of vaccines. However, the limited efficacy of DC vaccines hinders their widely application. This study redefines DC vaccines and provides a new DC‐BC vaccine that have much better therapeutic efficacy.
Xiangxiang Xu +11 more
wiley +1 more source
Editor’s Pick: PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy [PDF]
European Medical Journal Urology, 2016 Prostate-specific membrane antigen (PSMA) is the most extensively studied biomarker and antigen of prostate cancer. It is overexpressed in almost all prostate cancers, and the expression level increases with prostate cancer progression.
Wei Jin, Ashutosh Barve, Kun Cheng
doaj
Neoplasia: An International Journal for Oncology Research, 1999 The expression of immunoglobulin-based artificial receptors in normal T lymphocytes provides a means to target lymphocytes to cell surface antigens independently of major histocompatibility complex restriction.
Michael C. Gong +5 more
doaj +1 more source
LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1
Advanced Science, EarlyView.LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li +12 more
wiley +1 more source
Cancer biomarkers, and novel techniques for detection [PDF]
, 2017 Technologies for early detection of tumors is critical for better therapy outcome and overall change in cancer survival. These assays must be capable of detecting tumors at early stages in order to prevent metastasis of the tumor and help reduce ...
Jamal, Tameem
core
Antibody-drug conjugates targeting prostate-specific membrane antigen
Frontiers in Bioscience, 2014 Prostate-specific membrane antigen (PSMA) is an integral, non-shed membrane glycoprotein that is a well-characterized and clinically validated marker of prostate cancer. The expression profile and other biological properties of PSMA make it an attractive target for antibody-drug conjugate (ADC) therapy of prostate cancer, as well as a broad range of ...
William C, Olson, Robert J, Israel
openaire +2 more sources
Advanced Science, EarlyView.This study identifies B4GALNT4 as a key driver of prostate cancer (PCa). It shows that B4GALNT4 glycosylates PDK1 protein at the N531 site, which stabilizes the PDK1 and constitutively activates the PI3K‐AKT pathway. This mechanism promotes tumor cell proliferation, migration, and invasion. The findings establish the B4GALNT4‐PDK1 glycosylation axis as
Shaoqin Jiang +12 more
wiley +1 more source
Beyond the immune suppression: the immunotherapy in prostate cancer [PDF]
, 2015 Prostate cancer (PCa) is the second most common cancer in men.Aswell in many other human cancers, inflammation and immune suppression have an important role in their development.We briefly describe the host components that interact with the tumor to ...
Agliano', Anna Maria +4 more
core +3 more sources
Advanced Science, EarlyView.An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang +10 more
wiley +1 more source